Evidence map›Paper›PMID 40650489›Full record

ArticleClinical trials (London, England)2025

Nature-inspired metaheuristics for optimizing dose-finding and computationally challenging clinical trial designs.

Weng Kee Wong, Yevgen Ryeznik, Oleksandr Sverdlov, Ping-Yang Chen, Xinying Fang, Ray-Bing Chen, Shouhao Zhou, J Jack Lee

Abstract read
In one paragraph

Article in Clinical trials (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Weng Kee WongDepartment of Biostatistics, University of California, Los Angeles, CA, USA.ORCID 0000-0001-5568-3054
Yevgen RyeznikDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Oleksandr SverdlovAdvanced Quantitative Sciences, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Ping-Yang ChenDepartment of Statistics, National Taipei University, New Taipei City.
Xinying FangDepartment of Public Health Sciences, Pennsylvania State University, Hershey, PA, USA.
Ray-Bing ChenInstitute of Statistics and Data Science, National Tsing Hua University, Hsinchu.
Shouhao ZhouDepartment of Public Health Sciences, Pennsylvania State University, Hershey, PA, USA.
J Jack LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Metaheuristics are commonly used in computer science and engineering to solve optimization problems, but their potential applications in clinical trial design have remained largely unexplored. This article provides a brief overview of metaheuristics and reviews their limited use in clinical trial settings. We focus on nature-inspired metaheuristics and apply one of its exemplary algorithms, the particle swarm optimization (PSO) algorithm, to find phase I/II designs that jointly consider toxicity and efficacy. As a specific application, we demonstrate the utility of PSO in designing optimal dose-finding studies to estimate the optimal biological dose (OBD) for a continuation-ratio model with four parameters under multiple constraints. Our design improves existing designs by protecting patients from receiving doses higher than the unknown maximum tolerated dose and ensuring that the OBD is estimated with high accuracy. In addition, we show the effectiveness of metaheuristics in addressing more computationally challenging design problems by extending Simon's phase II designs to more than two stages and finding more flexible Bayesian optimal phase II designs with enhanced power.

Indexed as

Clinical Trials, Phase I as TopicClinical Trials, Phase II as TopicMaximum Tolerated DoseResearch DesignAlgorithmsDose-Response Relationship, DrugHumansContinuation-ratio modeldose-finding trialoptimal biological doseparticle swarm optimizationphase I/II trial

Identifiers

PMID40650489
PMCPMC12318163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.